191 related articles for article (PubMed ID: 30630775)
1. Age-targeted tuberculosis vaccination in China and implications for vaccine development: a modelling study.
Harris RC; Sumner T; Knight GM; Evans T; Cardenas V; Chen C; White RG
Lancet Glob Health; 2019 Feb; 7(2):e209-e218. PubMed ID: 30630775
[TBL] [Abstract][Full Text] [Related]
2. New tuberculosis vaccines in India: modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01
Clark RA; Weerasuriya CK; Portnoy A; Mukandavire C; Quaife M; Bakker R; Scarponi D; Harris RC; Rade K; Mattoo SK; Tumu D; Menzies NA; White RG
BMC Med; 2023 Aug; 21(1):288. PubMed ID: 37542319
[TBL] [Abstract][Full Text] [Related]
3. Potential impact of tuberculosis vaccines in China, South Africa, and India.
Harris RC; Sumner T; Knight GM; Zhang H; White RG
Sci Transl Med; 2020 Oct; 12(564):. PubMed ID: 33028708
[TBL] [Abstract][Full Text] [Related]
4. The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China.
Weerasuriya CK; Harris RC; McQuaid CF; Bozzani F; Ruan Y; Li R; Li T; Rade K; Rao R; Ginsberg AM; Gomez GB; White RG
BMC Med; 2021 Feb; 19(1):60. PubMed ID: 33632218
[TBL] [Abstract][Full Text] [Related]
5. Potential impact of spatially targeted adult tuberculosis vaccine in Gujarat, India.
Shrestha S; Chatterjee S; Rao KD; Dowdy DW
J R Soc Interface; 2016 Mar; 13(116):. PubMed ID: 27009179
[TBL] [Abstract][Full Text] [Related]
6. Affordability of Adult Tuberculosis Vaccination in India and China: A Dynamic Transmission Model-Based Analysis.
Weerasuriya CK; Harris RC; Quaife M; McQuaid CF; White RG; Gomez GB
Vaccines (Basel); 2021 Mar; 9(3):. PubMed ID: 33799544
[TBL] [Abstract][Full Text] [Related]
7. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
[TBL] [Abstract][Full Text] [Related]
8. Model-based impact evaluation of new tuberculosis vaccines in aging populations under different modeling scenarios: the case of China.
Tovar M; Sanz J; Moreno Y
Front Public Health; 2024; 12():1302688. PubMed ID: 38463158
[TBL] [Abstract][Full Text] [Related]
9. Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial.
Tameris M; Mearns H; Penn-Nicholson A; Gregg Y; Bilek N; Mabwe S; Geldenhuys H; Shenje J; Luabeya AKK; Murillo I; Doce J; Aguilo N; Marinova D; Puentes E; Rodríguez E; Gonzalo-Asensio J; Fritzell B; Thole J; Martin C; Scriba TJ; Hatherill M;
Lancet Respir Med; 2019 Sep; 7(9):757-770. PubMed ID: 31416768
[TBL] [Abstract][Full Text] [Related]
10. Population-level health and economic impacts of introducing Vaccae vaccination in China: a modelling study.
Mao JJ; Zang X; Yue WL; Zhai PY; Zhang Q; Li CH; Zhuang X; Liu M; Qin G
BMJ Glob Health; 2023 May; 8(5):. PubMed ID: 37257938
[TBL] [Abstract][Full Text] [Related]
11. Is neglect of self-clearance biasing TB vaccine impact estimates?
Scarponi D; Clark RA; Weerasuriya CK; Emery J; Houben RMGJ; White R; McCreesh N
BMJ Glob Health; 2023 Aug; 8(8):. PubMed ID: 37558271
[TBL] [Abstract][Full Text] [Related]
12. The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study.
Clark RA; Mukandavire C; Portnoy A; Weerasuriya CK; Deol A; Scarponi D; Iskauskas A; Bakker R; Quaife M; Malhotra S; Gebreselassie N; Zignol M; Hutubessy RCW; Giersing B; Jit M; Harris RC; Menzies NA; White RG
Lancet Glob Health; 2023 Apr; 11(4):e546-e555. PubMed ID: 36925175
[TBL] [Abstract][Full Text] [Related]
13. Modelling the effect of discontinuing universal Bacillus Calmette-Guérin vaccination in an intermediate tuberculosis burden setting.
Fu H; Lin HH; Hallett TB; Arinaminpathy N
Vaccine; 2018 Sep; 36(39):5902-5909. PubMed ID: 30143270
[TBL] [Abstract][Full Text] [Related]
14. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.
Ndiaye BP; Thienemann F; Ota M; Landry BS; Camara M; Dièye S; Dieye TN; Esmail H; Goliath R; Huygen K; January V; Ndiaye I; Oni T; Raine M; Romano M; Satti I; Sutton S; Thiam A; Wilkinson KA; Mboup S; Wilkinson RJ; McShane H;
Lancet Respir Med; 2015 Mar; 3(3):190-200. PubMed ID: 25726088
[TBL] [Abstract][Full Text] [Related]
15. Incidence of active tuberculosis in individuals with latent tuberculosis infection in rural China: follow-up results of a population-based, multicentre, prospective cohort study.
Gao L; Li X; Liu J; Wang X; Lu W; Bai L; Xin H; Zhang H; Li H; Zhang Z; Ma Y; Li M; Feng B; Du J; Sui H; Zhao R; Su H; Pan S; Guan L; Shen F; He J; Yang S; Si H; Cheng X; Xu Z; Tan Y; Chen T; Xu W; Peng H; Wang Z; Zhu T; Chen X; Zhou X; Guan X; Jin Q;
Lancet Infect Dis; 2017 Oct; 17(10):1053-1061. PubMed ID: 28716677
[TBL] [Abstract][Full Text] [Related]
16. NATCON 2022 Panel discussion: "TB vaccination - Going Forward".
Banurekha VV; Padmapriyadarsini C; Bhargava S; Sachdeva K
Indian J Tuberc; 2023 Jul; 70(3):366-369. PubMed ID: 37562914
[TBL] [Abstract][Full Text] [Related]
17. New tuberculosis vaccines in India: Modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01
Clark RA; Weerasuriya CK; Portnoy A; Mukandavire C; Quaife M; Bakker R; Scarponi D; Harris RC; Rade K; Mattoo SK; Tumu D; Menzies NA; White RG
medRxiv; 2023 Jul; ():. PubMed ID: 36865172
[TBL] [Abstract][Full Text] [Related]
18. Tuberculosis control strategies to reach the 2035 global targets in China: the role of changing demographics and reactivation disease.
Huynh GH; Klein DJ; Chin DP; Wagner BG; Eckhoff PA; Liu R; Wang L
BMC Med; 2015 Apr; 13():88. PubMed ID: 25896465
[TBL] [Abstract][Full Text] [Related]
19. The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study.
Portnoy A; Clark RA; Quaife M; Weerasuriya CK; Mukandavire C; Bakker R; Deol AK; Malhotra S; Gebreselassie N; Zignol M; Sim SY; Hutubessy RCW; Baena IG; Nishikiori N; Jit M; White RG; Menzies NA
PLoS Med; 2023 Jan; 20(1):e1004155. PubMed ID: 36693081
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
